P-291The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. (20th June 2018) - Ziranu, P; Demurtas, L; Puzzoni, M; Loupakis, F; Daniele, B; Rimassa, L; Bilancia, D; Lonardi, S; Avallone, A; Pella, N; Ferrari, D; Frassineti, L; et al.